Catheter ablation for persistent atrial fibrillation: A multicenter randomized trial of pulmonary vein isolation (PVI) versus PVI with posterior left atrial wall isolation (PWI) - The CAPLA study.


Journal

American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465

Informations de publication

Date de publication:
01 2022
Historique:
received: 07 06 2021
accepted: 28 09 2021
pubmed: 8 10 2021
medline: 8 4 2022
entrez: 7 10 2021
Statut: ppublish

Résumé

The success of pulmonary vein isolation (PVI) is reduced in persistent AF (PsAF) compared to paroxysmal AF. Adjunctive ablation strategies have failed to show consistent incremental benefit over PVI alone in randomized studies. The left atrial posterior wall is a potential source of non-PV triggers and atrial substrate which may promote the initiation and maintenance of PsAF. Adding posterior wall isolation (PWI) to PVI had shown conflicting outcomes, with earlier studies confounded by methodological limitations. To determine whether combining PWI with PVI significantly improves freedom from AF recurrence, compared to PVI alone, in patients with PsAF. This is a multi-center, prospective, international randomized clinical trial. 338 patients with symptomatic PsAF refractory to anti-arrhythmic therapy (AAD) will be randomized to either PVI alone or PVI with PWI in a 1:1 ratio. PVI involves wide antral circumferential pulmonary vein (PV) isolation, utilizing contact force sensing ablation catheters. PWI involves the creation of a floor line connecting the inferior aspect of the PVs, and a roof line connecting the superior aspect of the PVs. Follow up is for a minimum of 12 months with rhythm monitoring via implantable cardiac device and/or loop monitor, or frequent intermittent monitoring with an ECG device. The primary outcome is freedom from any documented atrial arrhythmia of > 30 seconds off AAD at 12 months, after a single ablation procedure. This randomized study aims to determine the success and safety of adjunctive PWI to PVI in patients with persistent AF.

Sections du résumé

BACKGROUND
The success of pulmonary vein isolation (PVI) is reduced in persistent AF (PsAF) compared to paroxysmal AF. Adjunctive ablation strategies have failed to show consistent incremental benefit over PVI alone in randomized studies. The left atrial posterior wall is a potential source of non-PV triggers and atrial substrate which may promote the initiation and maintenance of PsAF. Adding posterior wall isolation (PWI) to PVI had shown conflicting outcomes, with earlier studies confounded by methodological limitations.
OBJECTIVES
To determine whether combining PWI with PVI significantly improves freedom from AF recurrence, compared to PVI alone, in patients with PsAF.
METHODS
This is a multi-center, prospective, international randomized clinical trial. 338 patients with symptomatic PsAF refractory to anti-arrhythmic therapy (AAD) will be randomized to either PVI alone or PVI with PWI in a 1:1 ratio. PVI involves wide antral circumferential pulmonary vein (PV) isolation, utilizing contact force sensing ablation catheters. PWI involves the creation of a floor line connecting the inferior aspect of the PVs, and a roof line connecting the superior aspect of the PVs. Follow up is for a minimum of 12 months with rhythm monitoring via implantable cardiac device and/or loop monitor, or frequent intermittent monitoring with an ECG device. The primary outcome is freedom from any documented atrial arrhythmia of > 30 seconds off AAD at 12 months, after a single ablation procedure.
CONCLUSIONS
This randomized study aims to determine the success and safety of adjunctive PWI to PVI in patients with persistent AF.

Identifiants

pubmed: 34619143
pii: S0002-8703(21)00245-3
doi: 10.1016/j.ahj.2021.09.015
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

210-220

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

David Chieng (D)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia,; University of Melbourne, Melbourne, Australia; Cabrini Hospital, Melbourne, Australia.

Hariharan Sugumar (H)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia,; University of Melbourne, Melbourne, Australia; Cabrini Hospital, Melbourne, Australia.

Liang-Han Ling (LH)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia,; University of Melbourne, Melbourne, Australia; St Vincent's Private Hospital Fitzroy, Melbourne Australia.

Louise Segan (L)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia,; University of Melbourne, Melbourne, Australia; Cabrini Hospital, Melbourne, Australia.

Sonia Azzopardi (S)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia.

Sandeep Prabhu (S)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia,; University of Melbourne, Melbourne, Australia; Mulgrave Private Hospital, Melbourne, Australia.

Ahmed Al-Kaisey (A)

University of Melbourne, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia.

Aleksandr Voskoboinik (A)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia,; University of Melbourne, Melbourne, Australia; Cabrini Hospital, Melbourne, Australia.

Ramanathan Parameswaran (R)

University of Melbourne, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia.

Joseph B Morton (JB)

University of Melbourne, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia.

Bhupesh Pathik (B)

University of Melbourne, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia.

Alex J McLellan (AJ)

University of Melbourne, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia; St Vincent's Private Hospital Fitzroy, Melbourne Australia.

Geoffrey Lee (G)

University of Melbourne, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia.

Michael Wong (M)

University of Melbourne, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia; Epworth Hospital Richmond, Melbourne, Australia.

Sue Finch (S)

University of Melbourne, Melbourne, Australia.

Rajeev K Pathak (RK)

Canberra Hospital, ACT, Australia; Australian National University, ACT, Australia.

Deep Chandh Raja (DC)

Canberra Hospital, ACT, Australia; Australian National University, ACT, Australia.

Prashanthan Sanders (P)

Royal Adelaide Hospital, Adelaide, Australia.

Laurence Sterns (L)

Royal Jubilee Hospital, Vancouver Island, British Columbia, Canada.

Matthew Ginks (M)

John Radcliffe Hospital, Oxford, UK.

Christopher M Reid (CM)

Monash University, Melbourne, Australia; Curtin University, Perth, Australia.

Jonathan M Kalman (JM)

University of Melbourne, Melbourne, Australia; Monash University, Melbourne, Australia; Royal Melbourne Hospital, Melbourne, Australia.

Peter M Kistler (PM)

The Baker Heart and Diabetes Research Institute, Melbourne, Australia; The Alfred Hospital, Melbourne, Australia,; University of Melbourne, Melbourne, Australia; Cabrini Hospital, Melbourne, Australia; Monash University, Melbourne, Australia; Melbourne Private Hospital, Melbourne, Australia. Electronic address: Peter.kistler@baker.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH